These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
27. Growth after organ transplantation. Fuqua JS Semin Pediatr Surg; 2006 Aug; 15(3):162-9. PubMed ID: 16818137 [TBL] [Abstract][Full Text] [Related]
28. The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat. Tulipano G; Rossi E; Culler MD; Taylor JE; Bonadonna S; Locatelli V; Cocchi D; Giustina A Regul Pept; 2005 Feb; 125(1-3):85-92. PubMed ID: 15582718 [TBL] [Abstract][Full Text] [Related]
29. The role of growth hormone in glucocorticoid-induced osteoporosis. Lombardi G; Colarusso S; Di Somma C; Guerra E; Tauchmanova L; Colao A J Endocrinol Invest; 2008 Jul; 31(7 Suppl):38-42. PubMed ID: 18791350 [TBL] [Abstract][Full Text] [Related]
30. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency. Cavallo L; Gurrado R; Zecchino C; Manolo F; De Sanctis V; Cisternino M; Caruso-Nicoletti M; Galati M J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():845-9. PubMed ID: 10091155 [TBL] [Abstract][Full Text] [Related]
31. Growth hormone therapy in adults: rationales, results, and perspectives. Riedel M; Brabant G; Rieger K; von zur Mühlen A Exp Clin Endocrinol; 1994; 102(4):273-83. PubMed ID: 7813598 [TBL] [Abstract][Full Text] [Related]
34. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. De Nijs RN Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694 [TBL] [Abstract][Full Text] [Related]
35. Growth after renal transplantation in infancy or early childhood. Qvist E; Marttinen E; Rönnholm K; Antikainen M; Jalanko H; Sipilä I; Holmberg C Pediatr Nephrol; 2002 Jun; 17(6):438-43. PubMed ID: 12107809 [TBL] [Abstract][Full Text] [Related]
36. [The causes of the end of growth hormone treatment in children with chronic renal failure]. Leszczyńiska B; Ziółkowska H; Majcher A; Roszkowska-Blaim M Przegl Lek; 2006; 63 Suppl 3():153-5. PubMed ID: 16898517 [TBL] [Abstract][Full Text] [Related]
37. Recombinant human growth hormone for children with renal failure. Tönshoff B; Fine RN Adv Ren Replace Ther; 1996 Jan; 3(1):37-47. PubMed ID: 8620367 [TBL] [Abstract][Full Text] [Related]
38. Corticosteroids and growth. Fine RN Kidney Int Suppl; 1993 Oct; 43():S59-61. PubMed ID: 7902467 [TBL] [Abstract][Full Text] [Related]
39. Growth hormone therapy in the glucocorticosteroid-dependent child: metabolic and linear growth effects. Mauras N Horm Res; 2001; 56 Suppl 1():13-8. PubMed ID: 11786679 [TBL] [Abstract][Full Text] [Related]
40. Longitudinal growth in children following kidney transplantation: from conservative to pharmacological strategies. Ulinski T; Cochat P Pediatr Nephrol; 2006 Jul; 21(7):903-9. PubMed ID: 16773400 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]